These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

249 related articles for article (PubMed ID: 25672187)

  • 21. Rapid virological response assessment by Abbott RealTime hepatitis C virus assay for predicting sustained virological responses in patients with hepatitis C virus genotype 1 treated with pegylated-interferon and ribavirin.
    Su PY; Yen HH; Hsu YC; Wu SS; Kor CT; Su WW
    Kaohsiung J Med Sci; 2016 Jul; 32(7):381-6. PubMed ID: 27450028
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Predictive value of early virological response to treatment with different interferon-based regimens plus ribavirin in patients with chronic hepatitis C.
    Napoli N; Giannelli G; Parisi CV; Antonaci A; Maddalena G; Antonaci S
    New Microbiol; 2005 Jan; 28(1):13-21. PubMed ID: 15782622
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Rapid, early and sustained virological responses in a cohort of Irish patients treated with pegylated interferon and ribavirin for chronic hepatitis C virus infection.
    Sarwar S; Ryan EJ; Iqbal M; McCormick PA; O'Farrelly C; Hegarty J
    Ir J Med Sci; 2012 Mar; 181(1):53-8. PubMed ID: 22038749
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Role of rapid virological response in prediction of sustained virological response to Peg-IFN plus ribavirin in HCV / HIV co-infected individuals.
    Shea DO; Tuite H; Farrell G; Codd M; Mulcahy F; Norris S; Bergin C
    J Viral Hepat; 2008 Jul; 15(7):482-9. PubMed ID: 18221297
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Viral kinetic of HCV genotype-4 during pegylated interferon alpha 2a: ribavirin therapy.
    Derbala MF; El Dweik NZ; Al Kaabi SR; Al-Marri AD; Pasic F; Bener AB; Shebl FM; Amer AM; Butt MT; Yakoob R; John A; Al Mohanadi M; Al Khinji MA
    J Viral Hepat; 2008 Aug; 15(8):591-9. PubMed ID: 18482284
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Rapid virological response at week 4 predicts response to pegylated interferon plus ribavirin among HIV/HCV-coinfected patients.
    Mira JA; Valera-Bestard B; Arizcorreta-Yarza A; González-Serrano M; Torre-Cisneros J; Santos I; Vergara S; Gutiérrez-Valencia A; Girón-González JA; Macías J; López-Cortés LF; Pineda JA
    Antivir Ther; 2007; 12(4):523-9. PubMed ID: 17668561
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Plasma/erythrocyte ribavirin x100 ratio as an indicator of sustained virological response in HCV genotype 1 patients with early virological response.
    Baiocchi L; De Leonardis F; Delle Monache M; Nosotti L; Conti RL; Lenci I; Carbone M; Di Paolo D; Cucchiarelli S; Angelico M
    Antivir Ther; 2010; 15(4):633-9. PubMed ID: 20587856
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Rapid virological response and treatment duration for chronic hepatitis C genotype 1 patients: a randomized trial.
    Yu ML; Dai CY; Huang JF; Chiu CF; Yang YH; Hou NJ; Lee LP; Hsieh MY; Lin ZY; Chen SC; Hsieh MY; Wang LY; Chang WY; Chuang WL
    Hepatology; 2008 Jun; 47(6):1884-93. PubMed ID: 18508296
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Peginterferon alpha-2a and ribavirin versus peginterferon alpha-2a monotherapy in early virological responders and peginterferon alpha-2a and ribavirin versus peginterferon alpha-2a, ribavirin and amantadine triple therapy in early virological nonresponders: the SMIEC II trial in naïve patients with chronic hepatitis C.
    Angelico M; Koehler-Horst B; Piccolo P; Angelico F; Gentile S; Francioso S; Tarquini P; Vecchia RD; Ponti L; Pilleri G; Barlattani A; Grieco A; Soccorsi F; Guarascio P; Demelia L; Sorbello O; Rossi Z; Forlini G; Zaru S; Bandiera F;
    Eur J Gastroenterol Hepatol; 2008 Jul; 20(7):680-7. PubMed ID: 18679072
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Rapid virological response is the most important predictor of sustained virological response across genotypes in patients with chronic hepatitis C virus infection.
    Fried MW; Hadziyannis SJ; Shiffman ML; Messinger D; Zeuzem S
    J Hepatol; 2011 Jul; 55(1):69-75. PubMed ID: 21145856
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Optimal follow-up time to determine the sustained virological response in patients with chronic hepatitis C receiving pegylated-interferon and ribavirin.
    Namikawa M; Kakizaki S; Yata Y; Yamazaki Y; Horiguchi N; Sato K; Takagi H; Mori M
    J Gastroenterol Hepatol; 2012 Jan; 27(1):69-75. PubMed ID: 21649727
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Evaluation of early null response to pegylated interferon and ribavirin as a predictor of therapeutic nonresponse in patients undergoing treatment for chronic hepatitis C.
    Reau N; Satoskar R; Te H; DeVoss A; Elsen C; Reddy G; Mohanty S; Jensen D
    Am J Gastroenterol; 2011 Mar; 106(3):452-8. PubMed ID: 21063395
    [TBL] [Abstract][Full Text] [Related]  

  • 33. PREDICTIVE VALUE OF EARLY VIRIOLOGICAL RESPONSE FOR SUSTAINED VIRIOLOGICAL RESPONSE IN CHRONIC HEPATITIS WITH CONVENTIONAL INTERFERON THERAPY.
    Awan A; Umar M; Khaar Ht; Kulsoom A; Minhas Z; Ambreen S; Habib N; Mumtaz W; Habib F
    J Ayub Med Coll Abbottabad; 2016; 28(1):14-7. PubMed ID: 27323553
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Prediction of sustained virological response to combination therapy with pegylated interferon alfa and ribavirin in patients with genotype 3 chronic hepatitis C.
    Tohra SK; Taneja S; Ghosh S; Sharma BK; Duseja A; Dhiman RK; Das A; Chawla YK
    Dig Dis Sci; 2011 Aug; 56(8):2449-55. PubMed ID: 21706207
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Quantification of hepatitis C virus in patients treated with peginterferon-alfa 2a plus ribavirin treatment by COBAS TaqMan HCV test.
    Kanda T; Imazeki F; Yonemitsu Y; Mikami S; Takada N; Nishino T; Takashi M; Tsubota A; Kato K; Sugiura N; Tawada A; Wu S; Tanaka T; Nakamoto S; Mikata R; Tada M; Chiba T; Kurihara T; Arai M; Fujiwara K; Kanai F; Yokosuka O
    J Viral Hepat; 2011 Jul; 18(7):e292-7. PubMed ID: 21129130
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Predictive value of complete and partial early virological response on sustained virological response rates of genotype-4 chronic hepatitis C patients treated with PEG-interferon plus ribavirin.
    Elefsiniotis IS; Vezali E; Mihas C; Saroglou G
    Intervirology; 2009; 52(5):247-51. PubMed ID: 19602898
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Re-treatment of previous non-responders and relapsers to interferon plus ribavirin with peginterferon alfa-2a (40KD), ribavirin ± amantadine in patients with chronic hepatitis C: randomized multicentre clinical trial.
    Pessôa MG; Cheinquer H; Almeida PR; Silva GF; Lima MP; Paraná R; Lacerda MA; Parise ER; Pernambuco JR; Pedrosa SS; Teixeira R; Sette H; Tatsch F
    Ann Hepatol; 2012; 11(1):52-61. PubMed ID: 22166561
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Factors affecting efficacy in patients with genotype 2 chronic hepatitis C treated by pegylated interferon alpha-2b and ribavirin: reducing drug doses has no impact on rapid and sustained virological responses.
    Inoue Y; Hiramatsu N; Oze T; Yakushijin T; Mochizuki K; Hagiwara H; Oshita M; Mita E; Fukui H; Inada M; Tamura S; Yoshihara H; Hayashi E; Inoue A; Imai Y; Kato M; Miyagi T; Hohsui A; Ishida H; Kiso S; Kanto T; Kasahara A; Takehara T; Hayashi N
    J Viral Hepat; 2010 May; 17(5):336-44. PubMed ID: 19678893
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Optimizing outcomes in patients with hepatitis C virus genotype 1 or 4.
    Lee SS; Ferenci P
    Antivir Ther; 2008; 13 Suppl 1():9-16. PubMed ID: 18432158
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Early identification of HCV genotype 1 patients responding to 24 weeks peginterferon alpha-2a (40 kd)/ribavirin therapy.
    Jensen DM; Morgan TR; Marcellin P; Pockros PJ; Reddy KR; Hadziyannis SJ; Ferenci P; Ackrill AM; Willems B
    Hepatology; 2006 May; 43(5):954-60. PubMed ID: 16628671
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.